Positive Results Published for Gene Therapy in Friedreich Ataxia

Lexeo Therapeutics has shared promising data from its Phase I/II trials of LX2006 for Friedreich ataxia, indicating both safety and early efficacy. The publication in a reputable journal adds credibility to the findings and may pave the way for further research and development in gene therapies for this rare disease. This could represent a significant advancement in treatment options for affected patients.